Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ravaud

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Bulletin Du Cancer|February 22, 2001
[Cell therapy in solid tumors]A Ravaud
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
New challenges in kidney cancer therapy: bevacizumabA Ravaud
Asia-Pacific Journal of Clinical Oncology|August 28, 2020
Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than oneA Ravaud
Presse Medicale (Paris, France : 1983)|October 14, 1989
[Not value to the systematic study of different tumor markers for disclosing bone metastasis]A Ravaud
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 12, 2009
How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agentsA Ravaud
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2013
Clinical biomarkers of response in advanced renal cell carcinomaA Ravaud, M Schmidinger
The New England Journal of Medicine|May 1, 1999
Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective stateL Capuron, A Ravaud
Critical Reviews in Oncology/Hematology|October 26, 1999
Present achievements in the medical treatment of metastatic renal cell carcinomaA Ravaud, M Debled
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancerA Ravaud, M Sire
Pathologie-Biologie|March 15, 2006
[Renal cell carcinoma: the end of a tunnel?]A Ravaud, M-S Dilhuydy
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Bulletin Du Cancer|February 22, 2001
[Cell therapy in solid tumors]A Ravaud
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
New challenges in kidney cancer therapy: bevacizumabA Ravaud
Asia-Pacific Journal of Clinical Oncology|August 28, 2020
Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than oneA Ravaud
Presse Medicale (Paris, France : 1983)|October 14, 1989
[Not value to the systematic study of different tumor markers for disclosing bone metastasis]A Ravaud
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 12, 2009
How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agentsA Ravaud
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2013
Clinical biomarkers of response in advanced renal cell carcinomaA Ravaud, M Schmidinger
The New England Journal of Medicine|May 1, 1999
Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective stateL Capuron, A Ravaud
Critical Reviews in Oncology/Hematology|October 26, 1999
Present achievements in the medical treatment of metastatic renal cell carcinomaA Ravaud, M Debled
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancerA Ravaud, M Sire
Pathologie-Biologie|March 15, 2006
[Renal cell carcinoma: the end of a tunnel?]A Ravaud, M-S Dilhuydy
Pageof 11